Stocks Health care VVOS
NASDAQ · Health careVivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc. brought in $20.9M of revenue over the twelve months to June 30, 2026, up 45.2% from a year earlier. It posted a net loss of $25.5M. In fiscal 2025 capital spending exceeded operating cash flow by $17.6M. At June 30, 2026 it held $1.8M in cash against $582K of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Vivos Therapeutics, Inc. does
Vivos Therapeutics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker VVOS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $17.4M | -$21.2M | -$2.07 | -$17.6M |
| 2024 | $15M | -$11.1M | -$2.22 | -$13.3M |
| 2023 | $13.8M | -$13.6M | -$11.14 | -$12.7M |
| 2022 | $16M | -$23.8M | -$25.90 | -$20.5M |
| 2021 | $16.9M | -$20.3M | -$0.96 | -$18.1M |
| 2020 | $13.1M | -$12.1M | -$1.40 | -$5.8M |
Full financial statements: income, balance sheet and cash flow
Where VVOS ranks in Health care
Latest SEC filings
What Vivos Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 8, 2026Material agreement 8-K/A
- September 8, 2026
- September 3, 2026Passive stake changed SCHEDULE 13G/A
- August 21, 2026
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 35% to $5.2M versus the same quarter last year; diluted EPS -$0.31 versus -$0.55.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026Passive stake (5% or more) SCHEDULE 13G
- August 3, 2026
- July 15, 2026Activist stake (5% or more) SCHEDULE 13D
Insider trades
What the people running Vivos Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 31, 2026 | Amman Bradford K.Principal Accounting Officer | Received as pay | 250,000 | $102.5K |
| June 30, 2026 | Huntsman Ronald KirkChief Executive Officer, Director | Other changeindirect | 85,910 | $50K |
Who owns VVOS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| SP Manager LLC13D, may seek influence with 5 related filers | 19.9% | July 15, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 335,990 shares in total, about $47.3K at the last price.
| Holder | Shares |
|---|---|
| Amman Bradford K.Principal Accounting Officer | 250,080 |
| Huntsman Ronald KirkChief Executive Officer, Director | 85,91085,910 held indirectly |
Questions about VVOS
What does Vivos Therapeutics, Inc. do?
Vivos Therapeutics, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker VVOS.
Is Vivos Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $25.5M on revenue of $20.9M.
How much revenue does Vivos Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Vivos Therapeutics, Inc. reported revenue of $20.9M. That is 45.2% more than a year earlier.
When did Vivos Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 18, 2026.
Similar companies
Compare VVOS with
Follow VVOS
Get an email when Vivos Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VVOS: get an email when it filesWhere the numbers come from
Financial figures are the values Vivos Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.